002603 以岭药业
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)9.561-6.68612.08523.62614.941
总资产报酬率 ROA (%)7.265-4.7838.11816.15811.016
投入资产回报率 ROIC (%)9.144-5.8689.83219.72213.303

边际利润分析
销售毛利率 (%)60.53150.18757.28263.77163.615
营业利润率 (%)20.235-10.57817.24922.57715.510
息税前利润/营业总收入 (%)19.903-11.94216.57822.34615.529
净利润/营业总收入 (%)16.986-11.27313.02818.81313.261

收益指标分析
经营活动净收益/利润总额(%)99.48479.28094.947103.068100.217
价值变动净收益/利润总额(%)-0.010-4.9753.8770.414-1.409
营业外收支净额/利润总额(%)-1.51113.909-5.677-1.759-0.988

偿债能力分析
流动比率 (X)1.8461.6631.4721.4961.892
速动比率 (X)1.2850.9930.9191.0791.327
资产负债率 (%)24.77223.40332.63633.11129.699
带息债务/全部投入资本 (%)-0.284-0.44314.73316.3569.743
股东权益/带息债务 (%)-33,663.951-21,591.475554.734495.085889.909
股东权益/负债合计 (%)303.857327.983206.624202.053236.627
利息保障倍数 (X)-643.421-34.69964.873140.59390.712

营运能力分析
应收账款周转天数 (天)59.950100.23372.01247.93448.812
存货周转天数 (天)200.029233.312182.969146.462159.076